Detailed Narrative
Strategic Focus and Accomplishments
Since the close of fiscal 2022, Globus Medical has significantly scaled its business, tripling revenue and generating six times the free cash flow. During this period, the company closed two significant deals, extinguished almost $1 billion in debt, and deployed over $600 million to repurchase more than 10 million shares at an average price of $160 per share, offsetting over 25% of the dilution from the NuVasive merger. The company is now debt-free, generating significant free cash, and has launched over 30 new products, maintaining its DNA of innovation, execution, and financial prudence.
U.S. Spine Momentum
The U.S. Spine business continues to demonstrate strength and resilience, growing 10% in Q1 FY26, marking the third consecutive quarter of this growth rate and achieving 58 consecutive weeks of growth. This momentum is broad-based, with double-digit growth seen across categories such as standard fixation, MIS pedicle screws, expandable TLIF, ALIF posterior cervical, and cervical plating. Products like power tools and DuraPro are also contributing to new share capture and cross-selling opportunities, driven by competitive recruiting and robotics pull-through.
Enabling Technologies Strategy Shift
Enabling Technologies posted $26.9 million in revenue, growing 21% in Q1 FY26. The company is strategically altering its approach to capital acquisition, shifting from outright sales to a greater focus on leases and rentals. This change aims to more aggressively drive recurring revenue through implants, disposables, service, and case coverage, aligning with the goal of increasing implant procedure share. The robust pipeline is reflecting this mix shift, which is contemplated in the full-year revenue guidance, as leases and rentals result in different upfront revenue recognition compared to historical cash sales.
Trauma Business Performance
The Trauma business increased 30.4% over the prior year quarter, with growth stemming from both core trauma line share gains and the Precice Limb Lengthening portfolio. The ANTHEM Elbow plating system has exceeded expectations, with demand surpassing initial forecasts, leading to additional sets being delivered in Q2. Precice growth was driven by the ability to fully satisfy market demand after successfully transitioning manufacturing from former NuVasive facilities to Globus in early 2025, with output now exceeding historical levels.
Nevro Integration and Challenges
Nevro contributed $82.7 million in Q1 FY26 revenue, experiencing a sequential decline of $17.1 million or 17.1% compared to Q4 FY25. This lumpiness was anticipated due to structural changes in sales and marketing enacted at the end of 2025 as part of the strategy to rightsize the business and drive profitable sales growth. The team is actively recruiting new sales personnel, mapping new product introductions, and transitioning to a revised selling model, with expectations to return to a more historical run rate revenue late in the second half of the year.
Operational Discipline and Innovation
Globus Medical remains committed to achieving a mid-70s adjusted gross margin profile over the long term⏳, driven by ongoing manufacturing and supply chain initiatives. The company's approach to product development is focused on a ground-up mindset that integrates imaging, navigation, robotics, surgical intelligence, and implants to improve 10-year surgical outcomes to 95% or better. Surgical intelligence aims to create a closed-loop intelligent ecosystem to continuously enhance surgical outcomes.